Dublin, April 02, 2025 (GLOBE NEWSWIRE) -- The "Myocardial Infarction Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering.
The Myocardial Infarction market is expected to reach US$ 3.64 billion by 2033 from US$ 2.14 billion in 2024, with a CAGR of 6.08% from 2025 to 2033
The market for myocardial infarction is mostly being driven by the rising incidence of coronary artery disorders, which cause plaque to accumulate on the inner walls of the arteries and decrease blood supply to the heart muscle. Furthermore, another important element driving increase is the increasing incidence of several risk factors that are linked to it, including as smoking, excessive alcohol use, high cholesterol, and a lack of physical activity. 
Improved access to healthcare, lifestyle modifications, and heightened knowledge of cardiovascular health are further factors driving the industry's expansion. Myocardial infarctions are becoming more common due to risk factors like stress, smoking, poor diet, and physical inactivity, thus early detection and prevention are essential. The market is expanding because to advancements in pharmacological treatments, minimally invasive procedures, and diagnostic equipment that improve patient outcomes. Furthermore, chances for growth are being created by the emphasis on post-heart attack care, rehabilitation programs, and tailored medicine. But issues like exorbitant treatment prices and unequal access to healthcare still exist, especially in underdeveloped nations.
Primary endpoint findings from the open-label roll-in cohort of the CardiAMP cell treatment in chronic myocardial ischemia trial were published by BioCardia in May 2024. At the primary six-month follow-up endpoint, the open-label roll-in cohort of patients with refractory angina and chronic myocardial ischemia demonstrated an 82% decrease in angina episodes and an average increase in exercise tolerance of 107 seconds when compared to before starting the trial medication. Increased (better) exercise tolerance and a notable decrease in angina were signs that all of the patients responded well to treatment.
Growth Drivers for the Myocardial Infarction Market
Increasing Prevalence of Cardiovascular Diseases
The market for associated therapies and diagnostics is significantly driven by the rising prevalence of cardiovascular illnesses, especially myocardial infarction. The incidence of heart disease keeps rising as the world's population ages and lifestyle factors including smoking, poor food, lack of physical activity, and high levels of stress grow more common. The rise in cardiovascular diseases is driving up demand for both treatment alternatives like drugs, stents, and surgery, as well as diagnostic tools like biomarkers and sophisticated imaging methods.
Myocardial infarction has become a major focus for healthcare systems due to the need for preventive care, early identification, and efficient therapies. This has fueled advancements in medical technology and medications. Improving patient outcomes and lessening the strain on healthcare systems around the world depend on addressing these increasing rates.
Advancements in Diagnostic Technologies
The early identification and precise diagnosis of myocardial infarction are being greatly improved by advances in diagnostic technologies, which immediately improves treatment results. More accurate heart activity monitoring is made possible by innovations like improved electrocardiograms (ECGs), which speed up the identification of cardiac abnormalities. Furthermore, coronary angiography is now an essential tool for identifying coronary artery blockages, which enables prompt therapies like stent implantation or angioplasty.
More rapid and precise diagnosis of MI is also made possible by the development of cardiac biomarkers, which recognize particular proteins released during a heart attack. The MI market is growing as a result of these technologies, which not only make it easier to identify myocardial infarction early but also increase patient treatment, improving recovery, lowering complications, and improving prognosis.
Government Initiatives and Programs
The market is expanding as a result of the active measures being taken by governments and health organizations around the world to address the growing incidence of cardiovascular disorders, such as myocardial infarction. In addition to encouraging healthy lifestyles and early identification of heart diseases, these initiatives seek to increase public awareness of heart health.
Public health campaigns aimed at lowering risk factors including smoking, eating poorly, and not exercising are examples of preventive programs that are growing in popularity. In order to guarantee that patients with heart disease receive prompt interventions, governments are also expanding access to healthcare services and treatment alternatives. These programs are crucial in lowering the incidence of MI and bolstering the market for myocardial infarctions as a whole by financing research, giving treatment subsidies, and enhancing access to diagnostics and treatments.
Challenges in the Myocardial Infarction Market
Lack of Healthcare Access in Developing Regions
A major obstacle to the prompt diagnosis and treatment of myocardial infarction (MI) in many developing nations is the lack of access to medical facilities, diagnostic equipment, and qualified personnel. Remote and rural locations frequently lack the infrastructure needed to support sophisticated diagnostic tools like coronary angiography and ECGs, which are crucial for early heart attack detection.
Furthermore, a lack of qualified cardiologists and other medical professionals postpones appropriate treatment, which worsens patient outcomes and raises mortality rates. The problem is made worse by the delay in delivering life-saving procedures like angioplasty or medications that dissolve clots. The effectiveness of myocardial infarction care is hampered by these impediments to healthcare access, which also emphasize the need for better infrastructure and healthcare delivery systems in these areas.
Side Effects and Drug Resistance
Treating myocardial infarction (MI) presents major hurdles due to side effects and treatment resistance. For example, some patients may experience allergic reactions or gastrointestinal bleeding as a result of antiplatelet medications, which are frequently used to prevent blood clots following a heart attack. Furthermore, some people may not respond well to these medications because of genetic variables, which could result in less-than-ideal results. This variation highlights the need for more individualized and customized treatment plans that modify medicines according to a patient's genetic profile, medical background, and particular risk factors. A crucial area for future advancement in cardiovascular care, customized medicine has the potential to improve overall patient outcomes, decrease side effects, and increase the efficacy of MI treatments.
Company Analysis: Overview, Recent Development, Revenue Analysis
- Pfizer
- Sanofi-Aventis/Bristol-Myers Squibb
- AstraZeneca
- Merck
- Daiichi Sankyo
- Eli Lilly and Company
- Takeda
- Novartis
- Genentech
- Amgen
- Regeneron/Sanofi
- Boehringer Ingelheim
- Idorsia Pharmaceuticals
- Faraday Pharmaceuticals
- CSL Behring
- Immediate Therapeutics
- Mitsubishi Chemical Group
- Kancera
- Bayer
- Recardio
- Mesoblast
Key Questions Answered in Report
1. How big is the Myocardial Infarction industry?
The global Myocardial Infarction market size was valued at US$ 2.14 billion in 2024 and is expected to reach US$ 3.64 billion in 2033.
2. What is the Myocardial Infarction growth rate?
The global Myocardial Infarction market is expected to expand at a compound annual growth rate (CAGR) of 6.08% from 2025 to 2033.
3. Who are the key players in Myocardial Infarction industry?
Some key players operating in the Myocardial Infarction market includes Pfizer Inc., Bristol-Myers Squibb Co, AstraZeneca plc., Merck KGaA., Daiichi Sankyo Co Ltd, Novartis International AG, Genentech, Amgen, Regeneron, Takeda.
4. What are the factors driving the Myocardial Infarction industry?
Rising rates of cardiovascular disease, aging populations, increased access to healthcare, enhanced diagnostic and therapeutic options, changing lifestyles, and improvements in medicines and medical equipment are all factors driving the myocardial infarction market.
5. Which Region held the largest market share in the Myocardial Infarction industry?
North America is expected to hold the largest market share in the industry.
6. What segments are covered in the Myocardial Infarction Market report?
Drug Class, Distribution Channel and Countries segment are covered in this report.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value (USD) in 2024 | $2.14 Billion |
| Forecasted Market Value (USD) by 2033 | $3.64 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
Key Topics Covered:
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Exploring the Disease - Background and Key Insights
5.1 Introduction
5.2 Risk Factors
5.3 Pathophysiology
5.4 Diagnosis
5.5 Biomarkers
5.5.1 Biomarkers Originated from Myocardial Tissues
5.5.2 Biomarkers Induced by MI Incidence
5.5.3 Biomarkers Preexisted Before MI Occurred
5.6 Understanding Prior Myocardial Infarction - Definition and Overview
5.6.1 Recurrent MI
5.6.2 Reinfarction
5.6.3 Peri-procedural MI
5.7 Myocardial Infarction - WHO Criteria and Definition
5.7.1 Understanding MI in Category A: Definition and Diagnostic Standards
5.7.2 Category B definition and diagnostic criteria of MI if the requirements for diagnostic tests in Category A (above) Have Not Been Met
5.7.3 Understanding Probable MI in Category C: Definition and Diagnostic Standards
5.7.4 Fourth Universal Definition of Myocardial Infarction: Overview and Key Concepts
6. Comprehensive Treatment and Management
6.1 Antiplatelet agents
6.2 Anticoagulant agents
7. Practical Guidelines and Recommendations for Myocardial Infarction Care
7.1 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines: 2022
7.2 NICE Guidelines for Acute coronary syndromes: 2020
7.3 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation: 2017
7.4 Evidenced-based Recommendations from the Guidelines
7.5 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
8. Global Myocardial Infarction Market
9. Market Share
9.1 Drug Class
9.2 Distribution Channel
9.3 Country
10. Drug Class
10.1 Antiplatelet Agents
10.2 Glycoprotein IIb/IIIa Inhibitors
10.3 Antithrombotic Agents
10.4 Beta-adrenergic Blockers
10.5 Vasodilators
10.6 Angiotensin-converting Enzyme (ACE) Inhibitors
10.7 Angiotensin-receptor Blockers
10.8 Analgesics
10.9 Thrombolytics
11. Distribution Channel
11.1 Hospitals
11.2 Hospital Pharmacies
11.3 Drug Stores
11.4 Online Drug Stores
12. Country
12.1 North America
12.1.1 United States
12.1.2 Canada
12.2 Europe
12.2.1 France
12.2.2 Germany
12.2.3 Italy
12.2.4 Spain
12.2.5 United Kingdom
12.2.6 Belgium
12.2.7 Netherlands
12.2.8 Turkey
12.3 Asia Pacific
12.3.1 China
12.3.2 Japan
12.3.3 India
12.3.4 Australia
12.3.5 South Korea
12.3.6 Thailand
12.3.7 Malaysia
12.3.8 Indonesia
12.3.9 New Zealand
12.4 Latin America
12.4.1 Brazil
12.4.2 Mexico
12.4.3 Argentina
12.5 Middle East & Africa
12.5.1 South Africa
12.5.2 Saudi Arabia
12.5.3 UAE
13. Porter's Five Analysis
13.1 Bargaining Power of Buyers
13.2 Bargaining Power of Suppliers
13.3 Degree of Rivalry
13.4 Threat of New Entrants
13.5 Threat of Substitutes
14. SWOT Analysis
14.1 Strength
14.2 Weakness
14.3 Opportunity
14.4 Threat
15. Analysis of Marketed Therapies
15.1 Key Players
15.2 INSPRA (eplerenone): Pfizer
15.2.1 Description of Drug
15.2.2 Regulatory milestones
15.2.3 Safety and efficacy
15.3 PLAVIX (clopidogrel bisulfate): Sanofi-Aventis/Bristol-Myers Squibb
15.3.1 Description of Drug
15.3.2 Regulatory milestones
15.3.3 Safety and efficacy
15.4 BRILINTA (ticagrelor): AstraZeneca
15.4.1 Description of Drug
15.4.2 Regulatory milestones
15.4.3 Safety and efficacy
15.5 ZONTIVITY (vorapaxar): Merck
15.5.1 Description of Drug
15.5.2 Regulatory milestones
15.5.3 Safety and efficacy
15.6 EFFIENT/EFIENT (prasugrel): Daiichi Sankyo/Eli Lilly and Company
15.6.1 Description of Drug
15.6.2 Regulatory milestones
15.6.3 Safety and efficacy
15.7 ATACAND (candesartan): AstraZeneca/Takeda
15.7.1 Description of Drug
15.7.2 Regulatory milestones
15.7.3 Safety and efficacy
15.8 DIOVAN (valsartan): Novartis
15.8.1 Description of Drug
15.8.2 Regulatory milestones
15.8.3 Safety and efficacy
15.9 TNKASE (tenecteplase): Genentech
15.9.1 Description of Drug
15.9.2 Regulatory milestones
15.9.3 Safety and efficacy
15.10 REPATHA (evolocumab): Amgen
15.10.1 Description of Drug
15.10.2 Regulatory milestones
15.10.3 Safety and efficacy
15.11 PRALUENT (alirocumab): Regeneron/Sanofi
15.11.1 Description of Drug
15.11.2 Regulatory milestones
15.11.3 Safety and efficacy
16. Analysis of Emerging Therapies
16.1 Key Players
16.2 FARXIGA/FORXIGA (dapagliflozin): AstraZeneca
16.2.1 Description of Drug
16.2.2 Clinical Research & Development
16.2.3 Safety and efficacy
16.3 JARDIANCE (empagliflozin): Boehringer Ingelheim and Eli Lilly and Company
16.3.1 Description of Drug
16.3.2 Clinical Research & Development
16.3.3 Safety and efficacy
16.4 Pelacarsen (TQJ230): Novartis
16.4.1 Description of Drug
16.4.2 Clinical Research & Development
16.4.3 Safety and efficacy
16.5 Olpasiran: Amgen
16.5.1 Description of Drug
16.5.2 Clinical Research & Development
16.5.3 Safety and efficacy
16.6 Selatogrel: Idorsia Pharmaceuticals
16.6.1 Description of Drug
16.6.2 Clinical Research & Development
16.6.3 Safety and efficacy
16.7 FDY-5301: Faraday Pharmaceuticals
16.7.1 Description of Drug
16.7.2 Clinical Research & Development
16.7.3 Safety and efficacy
16.8 CSL112: CSL Behring
16.8.1 Description of Drug
16.8.2 Clinical Research & Development
16.8.3 Safety and efficacy
16.9 IMT-358: Immediate Therapeutics
16.9.1 Description of Drug
16.9.2 Clinical Research & Development
16.9.3 Safety and efficacy
16.10 CL2020: Mitsubishi Chemical Group
16.10.1 Description of Drug
16.10.2 Clinical Research & Development
16.10.3 Safety and efficacy
16.11 MEDI6570: AstraZeneca
16.11.1 Description of Drug
16.11.2 Clinical Research & Development
16.11.3 Safety and efficacy
16.12 KAND567: Kancera
16.12.1 Description of Drug
16.12.2 Clinical Research & Development
16.12.3 Safety and efficacy
16.13 Asundexian: Bayer
16.13.1 Description of Drug
16.13.2 Clinical Research & Development
16.13.3 Safety and efficacy
16.14 Dutogliptin: Recardio
16.14.1 Description of Drug
16.14.2 Clinical Research & Development
16.14.3 Safety and efficacy
16.15 MPC-25-IC: Mesoblast
16.15.1 Description of Drug
16.15.2 Clinical Research & Development
16.15.3 Safety and efficacy
17. Regulations and Reimbursement
17.1 PRALUENT (alirocumab)
17.2 INSPRA (eplerenone)
17.3 BRILINTA (ticagrelor)
17.4 REPATHA (evolocumab)
17.5 DIOVAN (valsartan)
17.6 ZONTIVITY (vorapaxar)
17.7 TNKase (tenecteplase)
17.8 Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)
Companies Featured
- Pfizer
- Sanofi-Aventis/Bristol-Myers Squibb
- AstraZeneca
- Merck
- Daiichi Sankyo
- Eli Lilly and Company
- Takeda
- Novartis
- Genentech
- Amgen
- Regeneron/Sanofi
- Boehringer Ingelheim
- Idorsia Pharmaceuticals
- Faraday Pharmaceuticals
- CSL Behring
- Immediate Therapeutics
- Mitsubishi Chemical Group
- Kancera
- Bayer
- Recardio
- Mesoblast
For more information about this report visit https://www.researchandmarkets.com/r/5nzk3y
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
